Is the Curative Thoracic Radiotherapy Benefit and Cost-Effective in Extensive Stage Small Cell Lung Cancer?

Diniz G.

SMALL CELL CARCINOMAS: CAUSES, DIAGNOSIS AND TREATMENT, ss.193-198, 2009 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası:
  • Basım Tarihi: 2009
  • Dergi Adı: SMALL CELL CARCINOMAS: CAUSES, DIAGNOSIS AND TREATMENT
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED)
  • Sayfa Sayıları: ss.193-198
  • Anahtar Kelimeler: SCLC, curative radiotherapy, palliative radiotherapy, survival benefit
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Lung cancer is the most common cause of cancer-related death and small cell lung cancer (SCLC) comprises about 15-20 % of all lung cancer cases. Majority of patients present with metastatic disease at diagnosis. Therapy regimens of SCLC include systemic chemotherapy, irradiation of primary tumor and/or metastases, adjuvant and prophylactic cranial radiotherapy, as well as medication of pain or other symptoms. Treatment is primarily dependent on the stage of SCLC and presence of metastases. Chemotherapy still is the cornerstone in treatment. The standard chemotherapy is the combination of etoposide and cisplatin. Despite initial sensitivity to therapy, >80% of the patients die from recurrent disease within 2 years.